medigraphic.com
ISSN 2007-2783 (Print)
Órgano Oficial del Instituto Científico Pfizer

2019, Number 2

<< Back Next >>

Residente 2019; 14 (2)

Sarcopenia and insulin resistance

Ramírez-Reyes A, Esparza-Guerrero Y, Ramírez-Villafaña M, Valdez-Balderrama JL, Chavero-Flores CA, Ordoñez-Pérez CA, Olivares-Ochoa XC, Rojo-Ruvalcaba BE, Pérez-Guerrero EE, Saldaña-Cruz AM

Language: Spanish
References: 47
Page: 47-54
PDF size: 308.94 Kb.


ABSTRACT

Sarcopenia is a pathological entity that leads to progressive loss of muscle mass, which leads to the development of multiple morbidities. In this article the diagnostic criteria for sarcopenia are discussed by the European Society of Geriatric Medicine (EWGSOP, 2018). Emphasis is placed on the timely detection and diagnosis, as well as the risk factors associated with the development of this disease, such as obesity, sedentary lifestyle, cachexia, nutritional diseases and insulin resistance. It has been described that insulin resistance has a high impact on muscle metabolism where the increase in adipose tissue acts in a synergistic manner for the final development of sarcopenia, increasing the production of involved cytokines such as tumor necrosis factor alpha TNF-α, interleukin-6 (IL-6), chemokine monocyte-1 (MCP-1) and resistin, which affect the muscle wear and the promotion of a toxic environment at the cellular level in adipose and muscle tissue.


REFERENCES

  1. Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr. 1997; 127: 990S-991S.

  2. Anker SD, Morley JE, Von Haehling S. Welcome to the ICD-10 code for sarcopenia. J Cachexia Sarcopenia Muscle. 2016; 7 (5): 512-514.

  3. Inouye SK, Studenski S, Tinetti ME, Kuchel GA. Geriatric syndromes: clinical, research, and policy implications of a core geriatric concept. J Am Geriatr Soc. 2007; 55 (5): 780-791.

  4. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T et al. Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019; 48: 16-31.

  5. World Health Organization. Ageing and life course. 2009 [Cited 2009 April 30]; Available from: http://www.who.int/ageing/en/.

  6. Velázquez AM, Irigoyen CM, Delgadillo VJ, Lazarevich. The relationship between sarcopenia, undernutrition, physical mobility and basic activities of daily living in a group of elderly women of Mexico City. Nutr Hosp. 2013; 514-521.

  7. Von Haehling S, Morley JE, Anker SD. An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle. 2010; 1 (2): 129-133.

  8. Arango-Lopera VE, Arroyo P, Gutiérrez-Robledo LM, Pérez-Zepeda MU. Prevalence of sarcopenia in Mexico City. European Geriatric Medicine. 2012; 3 (3): 157-160.

  9. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F et al. European working group on sarcopenia in older people. Age ageing. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing. 2010; 39: 412-423.

  10. Laurentani F, Russo C, Bandinelli S et al. Age-associated changes in skeletal muscles and their effect on mobility: an operational diagnosis of sarcopenia. J Appl Physiol. 2003; 95: 1851-1860.

  11. Baumgartner R, Koehler K, Gallagher D et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998; 147: 755-763.

  12. Cesari M, Kritchevsky SB, Newman AB et al. Added value of physical performance measures in predicting adverse health-related events: results from the health, aging and body composition study. J Am Geriatr Soc. 2009; 57: 251-259.

  13. Buchner DM, Larson EB, Wagner EH et al. Evidence for a non-linear relationship between leg strength and gait speed. Age Ageing. 1996; 25: 386-391.

  14. American Diabetes Association. “6. Glycemic Targets: Standards of Medical Care in Diabetes-2019”. Diabetes Care. 2019; 42 (Suppl 1): S61.

  15. Cleasby ME, Jamieson PM, Atherton PJ. Insulin resistance and sarcopenia: mechanistic links between common co-morbidities. J Endocrinol. 2016; 229: R67-81.

  16. Conley KE, Jubrias SA, Esselman PC. Capacidad oxidativa y envejecimiento en el músculo humano. Revista de Fisiología. 2000; 526: 203-210.

  17. Baumgartner RN. Body composition in healthy aging. Ann N Y Acad Sci. 2000; 904: 437-448.

  18. Umegaki H. Sarcopenia and frailty in older patients with diabetes mellitus. Geriatr Gerontol Int. 2016; 16: 293-299.

  19. Villareal DT, Banks M, Siener C et al. Physical frailty and body composition in obese elderly men and women. Obes Res. 2004; 12: 913-920.

  20. Rolland Y, Abellan van Kan G, Gillette-Guyonnet S, Vellas B. Cachexia versus sarcopenia. Curr Opin Clin Nutr Metab Care. 2011; 14: 15-21.

  21. Liccini A, Malmstrom TK. Frailty and sarcopenia as predictors of adverse health outcomes in persons with diabetes mellitus. J Am Med Dir Assoc. 2016; 17: 846-851.

  22. Leenders M, Verdijk LB, van der Hoeven L et al. Patients with type 2 diabetes show a greater decline in muscle mass, muscle strength, and functional capacity with aging. J Am Med Dir Assoc. 2013; 14: 585-592.

  23. Andreassen CS, Jakobsen J, Flyvbjerg A, Andersen H. Expression of neurotrophic factors in diabetes muscle-relation to neuropathy and muscle strength. Brain. 2009; 132: 2724-2733.

  24. Clark MG, Wallis MG, Barrett EJ et al. Blood flow and muscle metabolism: A focus on insulin action. Am J Physiol Endocrinol Metab. 2003; 284: E241-258.

  25. Shoelson SE. Inflammation and insulin resistance. J Clin Invest. 2006; 116 (7): 1793-1801.

  26. Aguirre V, Uchida T, Yenush L, Davis R, White MF. The c-Jun NH2-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser307. J Biol Chem. 2000; 275: 9047-9054.

  27. Hirosumi J et al. Un papel central para JNK en la obesidad y la resistencia a la insulina. Naturaleza. 2002; 420: 333-336.

  28. Summers SA. Ceramidas en resistencia a la insulina y lipotoxicidad. Prog Lipid Res. 2006; 45: 42-72.

  29. Feinstein R, Kanety H, Papa MZ, Lunenfeld B, Karasik A. Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem. 1993; 268: 26055-26058.

  30. Sishi B, Loos B, Ellis B, Smith W, du Toit EF, Engelbrecht AM. Diet-induced obesity alters signalling pathways and induces atrophy and apoptosis in skeletal muscle in a prediabetic rat model. Exp Physiol. 2011; 96: 179-193.

  31. Ussher JR, Koves TR, Cadete VJ, Zhang L, Jaswal JS, Swyrd SJ et al. Inhibition of de novo ceramide synthesis reverses diet-induced insulin resistance and enhances whole-body oxygen consumption. Diabetes. 2010; 59: 2453-2464.

  32. Chibalin AV, Leng Y, Vieira E, Krook A, Bjornholm M, Long YC et al. Downregulation of diacylglycerol kinase delta contributes to hyperglycemia-induced insulin resistance. Cell. 2008; 132: 375-386.

  33. Kim TN, Park MS, Yang SJ et al. Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes: the Korean Sarcopenic Obesity Study (KSOS). Diabetes Care. 2010; 33: 1497-1499.

  34. Abdulla H, Smith K, Atherton PJ, Idris I. Role of insulin in the regulation of human skeletal muscle protein synthesis and breakdown: a systematic review and meta-analysis. Diabetologia. 2015; 59 (1): 44-55.

  35. Sakuma K, Yamaguchi A. Sarcopenic obesity and endocrinal adaptation with age. Int J Endocrinol. 2013; 2013: 204164.

  36. Akhmedov D, Berdeaux R. The effects of obesity on skeletal muscle regeneration. Frontiers in Physiology. 2013; 4: 371.

  37. Greenberg AS, Egan JJ, Wek SA, Garty NB, Blanchette-Mackie EJ, Londos C. Perilipin, a major hormonally regulated adipocyte-specific phosphoprotein associated with the periphery of lipid storage droplets. J Biol Chem. 1991; 266 (17): 11341-11346.

  38. Bosma M, Kersten S, Hesselink MK, Schrauwen P. Re-evaluating lipotoxic triggers in skeletal muscle: Relating intramyocellular lipid metabolism to insulin sensitivity. Progress in Lipid Research. 2012; 51 (1): 36-49.

  39. Nascimento D, da C, da Cunha Oliveira S, Leite Vieira DC, Schwerz Funghetto S, Silva AO et al. The impact of sarcopenic obesity on inflammation, lean body mass, and muscle strength in elderly women. Int J Gen Med. 2018; 11: 443-449. doi:10.2147/ijgm.s187285.

  40. Umegaki H. Sarcopenia and frailty in older patients with diabetes mellitus. Geriatr Gerontol Int. 2016; 16: 293-299.

  41. Tan S, Li W, Wang J. Effects of six months of combined aerobic and resistance training for elderly patients with a long history of type 2 diabetes. J Sports Sci Med. 2012; 11: 495-501.

  42. Rahi B, Morais JA, Gaudreau P, Payette H, Shatenstein B. Energy and protein intakes and their association with a decline in functional capacity among diabetic older adults from the NuAge cohort. Eur J Nutr. 2016; 55 (4): 1729-1739.

  43. Wessels B, Ciapaite J, Van den Broek NM, Nicolay K, Prompers JJ. Metformin impairs mitochondrial function in skeletal muscle of both lean and diabetic rats in a dose dependent manner. PLoS ONE. 2014; 9: e100525.

  44. Rodríguez-Moctezuma JR, Robles-López G, López-Carmona JM, Gutiérrez-Rosas MJ. Effects of metformin on the body composition in subjects with risk factors for type 2 diabetes. Diabetes Obes Metab. 2005; 7: 189-192.

  45. Mele A, Calzolaro S, Cannone G, Cetrone M, Conte D, Tricarico D. Database search of spontaneous reports and pharmacological investigations on the sulfonylureas and glinides-induced atrophy in skeletal muscle. Pharmacol Res Perspect. 2014; 2: e00028.

  46. Lee CG, Boyko EJ, Barrett-Connor E et al. Insulin sensitizers may attenuate lean mass loss in older men with diabetes. Diabetes Care. 2011; 34: 2381-2386.

  47. Mensink M, Hesselink MK, Russell AP, Schaart G, Sels JP, Schrauwen P. Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1 alpha and PPAR beta/ delta gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus. Int J Obes (Lond). 2007; 31: 1302-1310.




2020     |     www.medigraphic.com